Medicine and Health Sciences Commons^™

Cost-Effectiveness And Outcomes Of Utilizing Tisagenlecleucel Therapy (Car T-Cell) In Pediatric Acute Lymphoblastic Leukemia In Comparison To Standard Of Care (Soc) Therapies: A Scoping Review, Andrew Atschinow, Evangeline Attota, Warren Chan, Pooja Kasarapu, Priyal Shah, Karina Vizzoni

Rowan-Virtua Research Day

Aims

This review aims to assess the correlations between outcomes and cost of treatment methods for pediatric acute lymphoblastic leukemia patients, specifically comparing CAR T-cell therapy and Standard-of-Care (SoC) therapy. The socioeconomic background of patients will also be taken into consideration to see if there are differences in their outcomes.

Methods

Peer-reviewed publications were collected from PubMed and Web of Science. The keyword strings used were “acute lymphoblastic leukemia,” “pediatric acute lymphoblastic leukemia,” “pediatric,” “CAR T-cell therapy,” and “cost-effectiveness.” 27 citations were obtained. Titles were screened by 6 authors. Articles met the inclusion criteria including potential Quality-Adjusted Life Year (QALY) …

Pediatric Acute Lymphoblastic Leukemia Treatment Effects On Neurocognitive Development, Peyton Lee Crowder

Epsilon Sigma at-Large Research Conference

Introduction

The problem at hand is understanding if pediatric acute lymphoblastic leukemia (ALL) treatment affects neurocognitive function or development. As the children battle ALL and are given treatments such as cranial radiation therapy and chemotherapy, they are having issues later on in life because the treatment regimens are very strong and are given during a crucial period of development.

Purpose Statement and Question

Does one pediatric treatment option affect neurocognitive development more than another later in life?

Literature Review

Research was conducted online via Google Scholar and East Tennessee State University Library database. Key terms used were pediatric ALL and …

Immunotherapy In Childhood Acute Lymphoblastic Leukemia, Gazmend Temaj

UBT International Conference

Acute lymphoblastic leukemia (ALL) is known as a heterogeneous disease. The progress is possible to make in understanding of biological mechanism who play pivotal role in the development of therapies. Here I will try to summarize the current and future possibilities of management of adult and children ALL. Many inhibitors are used to inhibit tyrosine kinase, chimeric antigen receptor and gene therapy for cure of ALL. The FDA has approved a number of drugs for treatment of children who are sick from ALL. Currently, is known that long term of survival is achieved in more than 50% of patients with …